Eris Lifesciences Limited has announced that India Ratings and Research (Ind-Ra) has affirmed the ‘IND AA/Stable/IND A1+’ credit ratings for the banking facilities of its wholly-owned subsidiary, Eris Therapeutics Limited (ETL). The rating agency also assigned fresh ratings to new credit facilities worth INR 1,000 million. This development highlights the subsidiary’s strong integration with its parent and robust operating performance within the Indian pharmaceutical market.
Rating Details and Scope
In a recent credit review, India Ratings has affirmed the ‘IND AA/Stable/IND A1+’ rating for INR 4,200 million in bank loan facilities previously held by Eris Therapeutics. Additionally, the agency assigned the same rating to new bank facilities totaling INR 1,000 million. This assessment reflects the agency’s confidence in the firm’s financial stability and its strategic role within the broader Eris Lifesciences group.
Strategic Financial Position
The rating action is underpinned by the parent company’s robust financial health. Eris Lifesciences reported consolidated EBITDA of INR 8.5 billion for the nine-month period ending December 2025 (9MFY26), compared to INR 7.6 billion in the same period last year. The company’s expansion into high-growth segments, such as injectables, insulin, and dermatology, has significantly diversified its portfolio.
Key Growth Drivers
The company’s growth strategy is heavily supported by successful mergers and acquisitions. Recent strategic moves, including the acquisition of Biocon Biologics’s Indian branded formulation business and full ownership of Swiss Parenterals Limited, have fast-tracked Eris’s entry into high-barrier therapeutic areas. These acquisitions have expanded the company’s manufacturing base to six facilities and strengthened its presence in the chronic therapy segment, which now accounts for 83% of its portfolio.
Outlook and Future Stability
Management anticipates that the integration of these acquired assets will drive further margin sustainability. The company’s consolidated net leverage improved to 2.2x in FY25, and projections suggest it will drop below 1.5x by FY27. With strong operational linkages, centralized treasury management, and corporate guarantees in place, Eris Therapeutics remains well-positioned to meet its capital requirements and debt obligations efficiently.
Source: BSE
